• Lamotrigine B2249: Reliable Assay Workflows

  2026-09-28

  Learn how Lamotrigine (SKU B2249) can support better-controlled cell viability, proliferation, and cytotoxicity workflows through defined purity, solvent guidance, and storage practices. This scenario-based guide also separates formulation effects from sodium-channel, serotonin, and CYP19-related biology.

• SHC-1 Inhibition and CFTR Surface Abundance

  2026-09-28

  This study tests whether SHC-1-dependent CFTR internalization occurs across airway and intestinal epithelial models, finding that the pathway is conserved but that increased surface CFTR after inhibitor treatment is limited to CFBE cells. The results highlight cell-model dependence and the need to distinguish changes in CFTR trafficking from broader changes in plasma-membrane protein abundance.

• 6-Thioguanine and DNMT1 in MCF-7 Cells

  2026-09-27

  This study links 6-thioguanine exposure in MCF-7 breast cancer cells with reduced DNMT1 expression, increased FAS and p21, apoptosis, and G2/M cell-cycle arrest. Its transcriptomic and cell-based assays suggest a mechanism for cancer cell proliferation inhibition, while leaving open whether DNMT1 changes directly cause the observed effects.

• Capture-and-Release Boosts Lateral Flow Sensitivity

  2026-09-26

  The AmpliFold strategy adds a triggered capture-and-release step to lateral flow assays, allowing analyte-bound complexes to be retained and then rebound through high-affinity interactions. In a HER2 proof of concept, the approach improved detection limits by up to 16-fold in low-density capture settings and by 12-fold with 150 nm gold nanoparticles, although broader validation is still needed.

• SHC-1 Inhibition and CFTR Surface Abundance

  2026-09-25

  The study tested whether SHC-1-linked CFTR internalization extends beyond CFBE airway cells and whether inhibiting this pathway raises CFTR at the plasma membrane. The pathway-related effect was observed across epithelial models, but increased surface CFTR after SHC-1 inhibitor treatment was limited to CFBE cells and was accompanied by changes in other membrane proteins, underscoring the importance of cell-model context.

• Axitinib (AG 013736) Assay Workflow Guide

  2026-09-25

  Build clearer VEGFR-response experiments with Axitinib (AG 013736), from endothelial signaling assays to cancer-model studies. Pair growth measurements with a death-specific readout to distinguish pathway inhibition from cell killing and improve interpretation.

• Chloroquine Pharmacogenomics: Evidence and Risk Phenotypes

  2026-09-24

  This systematic review brings together limited evidence that variants in CYP2C8, CYP3A5 and CYP2D6 may influence chloroquine and hydroxychloroquine safety or effectiveness. Its key contribution is a risk-phenotype framework that highlights potential variability across populations while underscoring the need for stronger clinical validation.

• TUDCA Workflows for ER Stress and Neuroprotection

  2026-09-24

  Tauroursodeoxycholic Acid (TUDCA) offers a practical way to test how ER stress, mitochondrial injury, and apoptosis contribute to cellular damage. This guide turns a subarachnoid hemorrhage study into a controlled assay workflow while distinguishing pathway-level evidence from TUDCA-specific conclusions.

• NF449 Dissects Platelet P2 Receptor Roles in Thrombosis

  2026-09-24

  Hechler and colleagues evaluated NF449 as a platelet P2X1 antagonist, showing that it inhibited P2X1 responses more potently than P2Y1 responses and had little effect on P2Y12 signaling in the assays tested. In mice, lower-dose treatment reduced platelet accumulation in thrombosis models without a statistically significant bleeding-time increase, whereas a higher dose inhibited all three platelet P2 receptors.

• Targeted PDT Needs Better Translational Proof

  2026-09-23

  How targeted photodynamic therapy research can move from impressive delivery results to rigorous, multimodal validation with fit-for-purpose fluorescence workflows.

• Axitinib Assay Workflows for VEGF Research

  2026-09-22

  Build more informative angiogenesis and cancer-response experiments with Axitinib (AG 013736), from VEGF pathway engagement to time-resolved viability and cell-death measurements. This workflow emphasizes practical dose design, solubility control, and the distinction between growth suppression and true cytotoxicity.

• Disodium Bicinchoninate in Redox Assays

  2026-09-22

  Disodium bicinchoninate is a water-compatible biochemical reagent whose value extends beyond simple protein quantification. This article connects its chemistry and handling requirements with assay-design lessons from a 2025 granulosa-cell inflammation study while clearly separating direct evidence from practical application.

• SB-505124 Hydrochloride and Cancer Cell Mechanics

  2026-09-21

  SB-505124 hydrochloride offers translational researchers a reversible way to interrogate ALK4/5/7-driven TGF-β and activin signaling alongside emerging models of cancer-cell mechanics. This article connects Smad pathway validation, fibrosis biology, formulation control, and AFM-based phenotyping while defining what the compound can—and cannot—establish about the MRTFA-KCNMB1 axis.

• PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition

  2026-09-21

  The reference study identifies low PPP2R2A expression, encoding the PP2A B55α regulatory subunit, as a potential biomarker for sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. Its experiments connect PPP2R2A deficiency with increased replication initiation, c-Myc-associated replication stress, and vulnerability that extends to models resistant to PARP inhibition.

• Oleanolic Acid: From iNOS Biology to Liposome Translation

  2026-09-20

  A translational perspective on how Oleanolic acid, inducible nitric oxide synthase induction, cyclooxygenase-2 modulation, and nanoparticle exclusion chromatography can be integrated into more rigorous antiviral and immune pathway research.

7992 records 1/533 page Next 12345 下5页 Last page